Potential and Therapeutic Efficacy of Cell-based Therapy Using Mesenchymal Stem Cells for Acute/chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Kidney disease can be either acute kidney injury (AKI) or chronic kidney disease (CKD) and it can lead to the development of functional organ failure. Mesenchymal stem cells (MSCs) are derived from a diverse range of human tissues. They are multipotent and have immunomodulatory effects to assist in the recovery from tissue injury and the inhibition of inflammation. Numerous studies have investigated the feasibility, safety, and efficacy of MSC-based therapies for kidney disease. Although the exact mechanism of MSC-based therapy remains uncertain, their therapeutic value in the treatment of a diverse range of kidney diseases has been studied in clinical trials. The use of MSCs is a promising therapeutic strategy for both acute and chronic kidney disease. The mechanism underlying the effects of MSCs on survival rate after transplantation and functional repair of damaged tissue is still ambiguous. The paracrine effects of MSCs on renal recovery, optimization of the microenvironment for cell survival, and control of inflammatory responses are thought to be related to their interaction with the damaged kidney environment. This review discusses recent experimental and clinical findings related to kidney disease, with a focus on the role of MSCs in kidney disease recovery, differentiation, and microenvironment. The therapeutic efficacy and current applications of MSC-based kidney disease therapies are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772 · cited 1×
“Many cytokines and natural/chemical compounds have been shown to have protective effects by enhancing cell survival and proliferation and modulating downstream pathways [89].”
BackgroundMesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease
Lai, R. C., Chen, T. S., & Lim, S. K. (2011) · Regenerative Medicine · doi:10.2217/rme.11.35 · Cited by 553 · cited 1×
“In addition, modulation of the immune system is another characteristic of MSCs and these cells were effective in treating several immune disorders in humans and animal models [28,29].”
BackgroundDrug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity
Perazella, M. A. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200306000-00006 · Cited by 225 · cited 1×
“Drug-induced nephrotoxicity is a one of the common causes of AKI, with an incidence as high as 60% [65,66].”
BackgroundChoi, J. R., Pingguan-Murphy, B., Wan Abas, W. A. B., Yong, K. W., Poon, C. T., Noor Azmi, M. A., Omar, S. Z., Chua, K. H., Xu, F., & Wan Safwani, W. K. Z. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115034 · Cited by 63 · cited 1×
“In addition, MSCs can secrete many different cytokines and growth factors, which regulate immune activity and enhance the potential of expansion and differentiation of host cells, thus promoting the recovery of damaged tissues [13].”
Background
Cited by
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Moeinabadi-Bidgoli, K., Babajani, A., Yazdanpanah, G., Farhadihosseinabadi, B., Jamshidi, E., Bahrami, S., & Niknejad, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112026 · Cited by 70
Amadeo, F., Trivino Cepeda, K., Littlewood, J., Wilm, B., Taylor, A., & Murray, P. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210013 · Cited by 20
Metadata
- Authors
- Yun, C. W., & Lee, S. H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-01
- Volume
- 20
- Issue
- 7
- Pages
- 1619
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2935614541
- Cited by
- 120
- References
- 4
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.